Medical technology company iSonea Ltd. (ASX: ISN; OTCQX: ISOAY), will be showcasing its asthma monitoring technology at the 2012 Annual HIMSS Conference & Exhibition being held at the Venetian-Sands Expo Convention Center in Las Vegas from February 21 – 23. Visit iSonea in the Qualcomm Life Pavilion Booth #13234.
iSonea will be showing its WheezoMeter? device and previewing the first version of its AsthmaSense? mobile health application — both designed to help asthma patients, their families, caregivers and physicians to monitor asthma symptoms on an ongoing basis.
iSonea’s WheezoMeter? device is based on the company’s Acoustic Respiratory Monitoring? (ARM) technology platform, which uses acoustic sensors and novel signal processing software to establish the presence, frequency and severity of wheeze. In essence a ‘thermometer’ for wheeze, the portable device records and analyzes sounds caused by inflammation or narrowing of the airways, to quantify the rate of wheezing, a hallmark symptom of asthma. The technology correlates to traditional lung function tests, but is more patient friendly, enabling frequent monitoring in real-life settings. The device requires no physical exertion and can be used to interpret respiratory symptoms by all asthma patients, including young children or the elderly.
The soon-to-be-introduced AsthmaSense? smartphone applications from iSonea will enable anyone, anywhere, at any time to better manage their asthma. Among the first version’s features, AsthmaSense will have a tracking system to monitor trends of symptoms, triggers, test results (peak flow measurements and WheezeRate?) and medication usage/ adherence.
iSonea recently announced a technology development initiative to design and market a home and mobile asthma monitoring platform. For more information on this collaborative platform, and for updates on HIMSS activities, go to http://www.iSoneaMed.com and follow SoundAsthma on Twitter (@soundasthma).
About iSonea Limited
iSonea Limited (ASX:ISN; OTCQX:ISOAY) is an emerging medical technology company developing innovative, non-invasive devices and mobile health apps to improve the management of chronic, costly respiratory disorders such as asthma and COPD. By leveraging iSonea’s proprietary Acoustic Respiratory Monitoring? (ARM) technology with its AsthmaSense? mobile applications, iSonea is turning smart phones into medical devices–enabling anyone, anywhere, at any time to monitor breathing distress symptoms, in order to take action. iSonea’s ARM devices have been cleared for use by the U.S. Food and Drug Administration, the Australian TGA and the European Union CE. For more information, please visit www.iSoneaMed.com.
Mr. Michael Thomas, +1 410-777-5251
Chief Executive Officer
Schwartz MSL Boston
Helen Shik or Jennifer Netzband, +1 781-684-0770